- Home
- LPTH vs ZNTL Comparison
LPTH vs ZNTL Comparison
Compare LPTH & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTH
- ZNTL
- Stock Information
- Founded
- LPTH 1985
- ZNTL 2014
- Country
- LPTH United States
- ZNTL United States
- Employees
- LPTH N/A
- ZNTL N/A
- Industry
- LPTH Semiconductors
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- LPTH Technology
- ZNTL Health Care
- Exchange
- LPTH Nasdaq
- ZNTL Nasdaq
- Market Cap
- LPTH 125.7M
- ZNTL 105.8M
- IPO Year
- LPTH 1996
- ZNTL 2020
- Fundamental
- Price
- LPTH $3.06
- ZNTL $1.47
- Analyst Decision
- LPTH Strong Buy
- ZNTL Buy
- Analyst Count
- LPTH 3
- ZNTL 7
- Target Price
- LPTH $4.67
- ZNTL $8.60
- AVG Volume (30 Days)
- LPTH 158.4K
- ZNTL 1.3M
- Earning Date
- LPTH 09-18-2025
- ZNTL 08-08-2025
- Dividend Yield
- LPTH N/A
- ZNTL N/A
- EPS Growth
- LPTH N/A
- ZNTL N/A
- EPS
- LPTH N/A
- ZNTL N/A
- Revenue
- LPTH $33,626,969.00
- ZNTL $26,865,000.00
- Revenue This Year
- LPTH $19.58
- ZNTL N/A
- Revenue Next Year
- LPTH $44.50
- ZNTL N/A
- P/E Ratio
- LPTH N/A
- ZNTL N/A
- Revenue Growth
- LPTH 2.59
- ZNTL N/A
- 52 Week Low
- LPTH $1.04
- ZNTL $1.01
- 52 Week High
- LPTH $4.42
- ZNTL $5.44
- Technical
- Relative Strength Index (RSI)
- LPTH 47.53
- ZNTL 58.18
- Support Level
- LPTH $3.06
- ZNTL $1.38
- Resistance Level
- LPTH $3.65
- ZNTL $1.52
- Average True Range (ATR)
- LPTH 0.22
- ZNTL 0.09
- MACD
- LPTH -0.03
- ZNTL 0.02
- Stochastic Oscillator
- LPTH 34.44
- ZNTL 85.07
About LPTH LightPath Technologies Inc.
LightPath Technologies Inc is a manufacturer, distributor, and integrator of proprietary optical components and assemblies. It is also engaged in the research and development for optical solutions for the traditional optics markets and communications markets. The company's business based on the following product groups: precision molded optics, specialty products, and infrared products. It currently serves the following major markets, distribution and catalog, laser, industrial, instrumentation, telecommunications, and defense.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.